Itameline

Drug Profile

Itameline

Alternative Names: RU 47213

Latest Information Update: 21 Jan 1997

Price : $50

At a glance

  • Originator Aventis
  • Class Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 21 Jan 1997 No-Development-Reported for Alzheimer's disease in France (PO)
  • 01 Nov 1994 Phase-I clinical trials for Alzheimer's disease in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top